Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Last trade$1.62
Day change-$0.04 (-2.41%)
Day range$1.60 – $1.65
Volume55,427
Market cap$18M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$18.38M
Price / earnings
—
Price / book
0.87×
Price / sales
5.66×
EV / sales
4.86×
EV / EBITDA
-1.5×
Profitability
Earnings per share
-$0.84
Return on assets
-40.22%
Return on equity
-44.09%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
11.36×
Quick ratio
11.36×
Cash ratio
1.28×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$10.01M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LPCN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.1M
$0
$0
$1.15M
$0
$500K
$0
$3.49M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$2.1M
$0
$0
$1.15M
$0
$500K
$0
$3.49M
Selling, general and administrative
$1.09M
$990.96K
$1.2M
$983.39K
$767.84K
$890.43K
$1.12M
$873.06K
Research and development
$2.07M
$2.04M
$2.76M
$2.68M
$2.71M
$2.14M
$1.06M
$1.07M
Total operating expenses
$3.16M
$3.03M
$3.97M
$3.66M
$3.48M
$3.03M
$2.18M
$1.95M
Operating income
-$1.06M
-$3.03M
-$3.97M
-$2.52M
-$3.48M
-$2.53M
-$2.18M
$1.55M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$666.19K
-$2.62M
-$3.67M
-$2.37M
-$3.19M
-$2.21M
-$1.86M
$1.78M
Income taxes
$0
$200
$0
$0
$0
$0
$200
$0
Net income
-$666.19K
-$2.62M
-$3.67M
-$2.37M
-$3.19M
-$2.21M
-$1.86M
$1.78M
Net income attributable to common shareholders
-$666.19K
-$2.62M
-$3.67M
-$2.37M
-$3.19M
-$2.21M
-$1.86M
$1.78M
EBITDA
-$1.04M
-$3.02M
-$3.95M
-$2.5M
-$3.46M
-$2.51M
-$2.17M
$1.56M
Basic earnings per share
-$0.08
-$0.32
-$0.54
-$0.42
-$0.59
-$0.41
-$0.35
$0.33
Diluted earnings per share
-$0.08
-$0.32
-$0.54
-$0.35
-$0.59
-$0.41
-$0.35
$0.32
Recent news
Company coverage with links to the original publishers.
Lipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis.
Lipocine announced 80% enrollment completion in its Phase 3 clinical trial for LPCN 1154, an oral brexanolone treatment for postpartum depression. The study is on track for topline results in Q2 2026, with 66 of 80 planned participants randomized.
Lipocine Inc. announced it will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, showcasing its proprietary oral drug delivery technology and clinical development candidates.
The sarcopenia market remains largely untapped, with significant unmet medical needs and no approved drug therapies. However, pharmaceutical interest is rising, particularly around muscle-enhancing agents and anti-inflammatory pathways. Regulatory bodies are beginning to recognize sarcopenia as a distinct clinical condition, which may streamline future drug approvals.
Lipozem, a turmeric-based supplement, claims to address the root cause of stubborn weight gain - inflammation within fat cells. Consumer reports highlight remarkable weight loss results, with some users losing over 90 lbs in just 3 months. The supplement's unique formula, developed by Dr. Julian Ross, targets inflammation directly, enabling natural and sustained fat burning.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.